Method of making a mycoplasma vaccine

US9273281B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9273281-B2
Application numberUS-201314135796-A
CountryUS
Kind codeB2
Filing dateDec 20, 2013
Priority dateDec 28, 2012
Publication dateMar 1, 2016
Grant dateMar 1, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to a method for the preparation of an immunogenic composition for the treatment and/or prophylaxis of mycoplasma infections in a subject comprising the cultivation of mycoplasma bacteria in a serum-reduced or swine serum-free, eukaryotic cell system; obtaining an antigen of the mycoplasma bacteria; and addition of a pharmaceutically acceptable carrier. Further, the present invention relates to the immunogenic composition obtainable by said method and a method for immunizing a subject comprising the administration of said immunogenic composition to a subject.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method for the preparation of an immunogenic composition for the treatment of mycoplasma infections in a subject comprising a bacterin comprising one or more antigens selected from M. hyorhinis, M. hyosynoviae , and M. hyopneumoniae , and any combination thereof, wherein at least one of bacteria M. hyorhinis, M. hyosynoviae , and/or M. hyopneumoniae is co-cultivated in a eukaryotic cell system comprising McCoy cells comprising the steps of: a. cultivating mycoplasma in a serum-reduced, McCoy cell system; b. obtaining such a mycoplasma bacteria as a bacterin comprising mycoplasma antigens; and c. adding a pharmaceutically acceptable carrier. 2. The method of claim 1 , wherein the serum is free of swine serum. 3. The method of claim 1 , wherein the mycoplasma bacteria are cultivated in the absence of serum. 4. The method of claim 1 , wherein the antigen has an increased immunogenicity compared to an antigen obtained from mycoplasma bacteria cultivated in a cell free culturing system. 5. The method of claim 1 , wherein the bacterins are formalin or binary ethylenimine (BEI) inactivated bacterins. 6. The method of claim 1 , wherein the immunogenic composition comprises a bacterin comprising a combination of antigens of M. hyorhinis and M. hyopneumoniae. 7. The method of claim 1 , wherein the immunogenic composition comprises a bacterin comprising a combination of antigens of M. hyopneumoniae, M. hyorhinis and M. hyosynoviae. 8. The method of 1, wherein said immunogenic composition is formulated for a single-dose administration. 9. The method of claim 1 , wherein said subject is a swine. 10. The method of claim 1 , wherein said pharmaceutically acceptable carrier is selected from the group consisting of solvents, dispersion media, coatings, stabilizing agents, diluents, preservatives, antibacterial and antifungal agents, isotonic agents, adsorption delaying agents, adjuvants, immune stimulants, and combinations thereof. 11. The method of claim 1 , wherein said pharmaceutically acceptable carrier is an adjuvant selected from the group consisting of aluminum hydroxide, aluminum phosphate, saponins, water-in-oil emulsion, oil-in-water emulsion, water-in-oil-in-water emulsion, polymers of acrylic or methacrylic acid, copolymers of maleic anhydride and alkenyl derivative, the RIBI adjuvant system, Block co-polymer, SAF-M, monophosphoryl lipid A, Avridine lipid-amine, heat-labile enterotoxin from E. coli (recombinant or otherwise), cholera toxin, IMS 1314, muramyl dipeptide, and combinations thereof. 12. The method of claim 1 , wherein said pharmaceutically acceptable carrier is a water-in-oil-in-water emulsion or a carbomer.

Assignees

Inventors

Classifications

  • Antibacterial agents · CPC title

  • Immunostimulants · CPC title

  • C12N1/20Primary

    Bacteria; Culture media therefor · CPC title

  • Adaptation or attenuation of cells · CPC title

  • Kidney cells · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9273281B2 cover?
The present invention relates to a method for the preparation of an immunogenic composition for the treatment and/or prophylaxis of mycoplasma infections in a subject comprising the cultivation of mycoplasma bacteria in a serum-reduced or swine serum-free, eukaryotic cell system; obtaining an antigen of the mycoplasma bacteria; and addition of a pharmaceutically acceptable carrier. Furthe…
Who is the assignee on this patent?
Jordan Dianna M Murphy, Martinson Brian Thomas, Muehlenthaler Christine Margaret, and 3 more
What technology area does this patent fall under?
Primary CPC classification C12N1/20. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Mar 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).